A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of "Nexthaler" Dry Powder Inhaler in COPD Patients

NCT02000609 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: CHF 1535 NEXThaler 800/48
DRUG: CHF 1535 NEXThaler 200/12
DRUG: CHF 1535 NEXThaler PLACEBO
DRUG: CHF 1535 pMDI 200/12
DRUG: CHF1535 pMDI 800/48

Sponsor

Chiesi Farmaceutici S.p.A.